Primary outcomes included changes in liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatic steatosis and fibrosis indices including controlled attenuation parameter (CAP), liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), and the MASLD fibrosis score (NFS), and secondary outcomes included lipid parameters, glycemic control, and anthropometric measures.<h4>Results</h4>Eight RCTs involving 672 participants (353 empagliflozin and 319 placebo) were included. The gene discussed is GPT; the disease is Hepatic steatosis.